Patritumab deruxtecan
As of the edition of 20 October 2026, Patritumab deruxtecan is an antibody drug conjugate: in active development; acts on ERBB3 and TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 28, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system; Nervous system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 0 | 2 | 0 |
| Phase 2 | 22 | 3 | 17 | 2 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 28 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Lead sponsor of trials | 2016 to now |
| Merck & Co. | Lead sponsor of trials | 2019 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2021 to now |